Novartis | NVS - Ebit


Novartis reported $4.48B in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bausch Health Companies USD 719M 2M Dec/2025
Biogen USD 659.6M 157M Sep/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Canopy Growth CAD -14.3M 17.19M Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Drreddys Laboratories INR 16.37B 3.5B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Novartis USD 4.48B 343M Sep/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
Phibro Animal Health USD 26M 5.54M Sep/2024
Prestige Brands USD 82.49M 2.82M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 3.74B 2.23B Sep/2025
Supernus Pharmaceuticals USD -60.18M 72.33M Sep/2025
Zoetis USD 835M 140M Dec/2025